Literature DB >> 12394969

Sickle cell disease, extreme hyperbilirubinemia, and pericardial tamponade: case report and review of the literature.

Imtiaz Khurshid1, Linda Anderson, Gordon H Downie, Gregory S Pape.   

Abstract

OBJECTIVE: Sickle cell disease is a relatively common disease seen predominantly in the African-American population with numerous important sequelae that require critical care management. We report a patient who presented with intrahepatic cholestasis, a rare and potentially lethal complication of sickle cell disease.
DESIGN: Individual case report and review of the literature.
SETTING: Medical intensive care unit of a tertiary care hospital. PATIENT: A 37-yr-old African-American male, with known sickle cell disease, who developed fulminant hepatic failure with subsequent extreme hyperbilirubinemia, coagulopathy, and pericardial tamponade. Additional organ dysfunction included renal insufficiency, respiratory failure, and cardiac dysrhythmias.
INTERVENTIONS: The patient underwent serial measurements of complete blood count, hepatic profile, coagulation profiles, and hemoglobin electrophoresis. The patient received exchange transfusion, and his hemoglobin S concentration gradually decreased. Coagulopathy and anemia were corrected with transfusion of fresh frozen plasma and packed red blood cells. Serum bilirubin and other hepatic variables gradually improved. Pericardial tamponade was suggested by right heart catheterization measurements and diagnosed by echocardiographic findings. The tamponade resolved after pericardiocentesis and was managed by drainage through the pericardial catheter. Pulmonary, renal, and cardiac sequelae resolved with intensive supportive care that included intubation, mechanical ventilation, pulmonary artery catheterization, continuous renal replacement therapy, and permanent cardiac pacemaker. The patient was discharged home on hospital day 23 and has not required further hospitalization.
CONCLUSION: Sickle cell intrahepatic cholestasis, a potentially fatal complication of sickle cell disease, can present with abdominal pain, acute hepatomegaly, coagulopathy, hyperbilirubinemia, and fulminant hepatic failure. Prompt recognition and early intervention with exchange transfusion and intensive supportive care of multiple organ dysfunction can result in a favorable outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12394969     DOI: 10.1097/00003246-200210000-00029

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

1.  Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient.

Authors:  Daniel B Costa; Rebecca A Miksad; Michael S Buff; Yihong Wang; Bruce J Dezube
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

Review 2.  Interventions for treating intrahepatic cholestasis in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

3.  Reversal of liver function without exchange transfusion in sickle cell intrahepatic cholestasis.

Authors:  Nattamol Hosiriluck; Supannee Rassameehiran; Erwin Argueta; Lukman Tijani
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-10

Review 4.  Acute liver function decompensation in a patient with sickle cell disease managed with exchange transfusion and endoscopic retrograde cholangiography.

Authors:  Haris Papafragkakis; Mel A Ona; Kinesh Changela; Swayamprabha Sadanandan; Abraham Jelin; Sury Anand; Sushil Duddempudi
Journal:  Therap Adv Gastroenterol       Date:  2014-09       Impact factor: 4.409

Review 5.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

6.  Liver Transplantation in Patients with Sickle Cell Disease in the United States.

Authors:  Rachel Hogen; Michelle Kim; Yelim Lee; Mary Lo; Navpreet Kaur; Jeff Kahn; Shefali Chopra; Yasir Qazi; Ashraf Sedra; Jim Kim; Lauren O'Brien; Yuri Genyk; Linda Sher; Juliet Emamaullee
Journal:  J Surg Res       Date:  2020-06-12       Impact factor: 2.192

7.  Intrahepatic cholestasis in sickle cell disease: a case report.

Authors:  Denise Menezes Brunetta; Ana Cristina Silva-Pinto; Maria do Carmo Favarin de Macedo; Sarah Cristina Bassi; Joao Victor Piccolo Feliciano; Fernanda Borges Ribeiro; Benedito de Pina Almeida Prado; Gil Cunha De Santis; Ivan de Lucena Angulo; Dimas Tadeu Covas
Journal:  Anemia       Date:  2010-12-21

8.  Interventions for treating intrahepatic cholestasis in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-06-22

9.  Marked Direct Hyperbilirubinemia due to Ceftriaxone in an Adult with Sickle Cell Disease.

Authors:  Daniyeh Khurram; Leonid Shamban; Robert Kornas; Maryann Paul
Journal:  Case Rep Gastrointest Med       Date:  2015-05-25

10.  Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S.

Authors:  Arianna Barbetta; Cameron Goldbeck; Angelina Lim; Sean P Martin; Jeffrey A Kahn; M Raashid Sheikh; Juliet Emamaullee
Journal:  HPB (Oxford)       Date:  2021-07-06       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.